Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52

OBJECTIVES: SPIRIT head-to-head (H2H) is a 52-week (Wk) trial comparing ixekizumab (IXE) with adalimumab (ADA) for simultaneous American College of Rheumatology (ACR)50 and Psoriasis Area and Severity Index (PASI)100 responses in 566 patients (distributed evenly across both groups) with psoriatic ar...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Ann Rheum Dis
Huvudupphovsmän: Smolen, Josef S, Mease, Philip, Tahir, Hasan, Schulze-Koops, Hendrik, de la Torre, Inmaculada, Li, Lingnan, Hojnik, Maja, Sapin, Christophe, Okada, Masato, Caporali, Roberto, Gratacós, Jordi, Goupille, Philippe, Liu Leage, Soyi, Pillai, Sreekumar, Nash, Peter
Materialtyp: Artigo
Språk:Inglês
Publicerad: BMJ Publishing Group 2020
Ämnen:
Psoriatic Arthritis
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7509529/
https://ncbi.nlm.nih.gov/pubmed/32660977
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2020-217372
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk